Specialty Pharmacy Program Drug List
|
|
|
- Shana Holland
- 8 years ago
- Views:
Transcription
1 Specialty Pharmacy Program Drug List The Specialty Pharmacy Program covers certain drugs commonly referred to as high-cost Specialty Drugs. To receive in-network benefits/coverage for these drugs, these drugs must be dispensed through a select group of contracted specialty pharmacies or your medical provider. Please call the BCBSLA Customer Service number on the back of your member ID card for information about our contracted specialty pharmacies. All specialty drugs listed below are limited to the retail day supply listed in your benefit plan (typically a 30-day supply). Inclusion on this list does not imply benefits. Please refer to your benefit plan for a complete list of benefits, including specific exclusions, limitations and member cost-sharing amounts you are responsible for such as a deductible, copayment and coinsurance. Brand Name Generic Name Drug Classification 8-MOP methoxsalen Psoralen Actemra SC tocilizumab Monoclonal Antibody/Arthritis Acthar corticotropin Adrenocortical insufficiency Actimmune interferon gamma 1b Interferon Adcirca tadalafil Pulmonary Arterial Hypertension Adempas riociguat Chronic Thromboembolic Pulmonary Hypertension/ Pulmonary Arterial Hypertension Afinitor everolimus Oncology Alferon interferon alfa-n3 Interferon Ampyra ER dalfampridine Multiple Sclerosis Aptivus tipranavir HIV/AIDS Apokyn apomorphine Parkinson's Disease Aranesp darbepoetin alfa Red blood cell progenitor Arcalyst rilonacept Interleukin Blocker/ CAPS Atripla efavirenz/emtricitabine/tenofovir HIV/AIDS Aubagio teriflunomide Multiple Sclerosis Avonex interferon beta-1a Multiple Sclerosis Baraclude entecavir Hepatitis B Berinert C1 esterase inhibitor Hereditary Angioedema Betaseron beta-interferon 1B Multiple Sclerosis Bosulif bosutinib Oncology Buphenyl sodium phenylbutyrate Nitrogen-binding Agent Caprelsa vandetanib Oncology Carbaglu carglumic acid Endocrine Agent Cayston aztreonam lysine Cystic Fibrosis Cetrotide cetrorelix Specialized OB/GYN Chemet succimer Chelating Agent Chenodal chenodiol Gallstone Solubilizing Agent
2 Cimzia certolizumab pegol Anti Tumor Necrosis Factor Drug Cinryze C1 esterase inhibitor Hereditary Angioedema Combivir lamivudine/zidovudine* HIV/AIDS Cometriq cabozantinib s-malate Oncology Complera emtricitabine/rilpivirine/tenofovir HIV/AIDS Copaxone glatiramer acetate Multiple Sclerosis Copegus ribavirin* Hepatitis C Cystadane betaine Homocystinuria Cystaran cysteamine Cystine-depleting Agent Daklinza dackatasvur dihydrochloride Hepatitis C DDAVP nasal desmopressin* Vasopressin Analogue spray/rhinal tube Edurant rilpivirine HIV/AIDS Egrifta tesamorelin Growth Hormonee Emtriva emtricitabine HIV/AIDS Enbrel etanercept Anti tumor necrosis factor drug/arthritis/psoriasis Epivir lamivudine* HIV/AIDS Epivir-HBV lamivudine* Hepatitis B Epogen epoetin alfa Red blood cell progenitor Epzicom abacavir/lamivudine HIV/AIDS Erbitux cetuximab Oncology Erivedge vismodegib Oncology Erwinaze asparaginase Oncology Exjade deferasirox Chelating agent Extavia interferon beta-1b Interferon Ferriprox deferiprone Iron overload Fertinex urofollitropin Ovulatory Stimulants Firazyr icatibant Hereditary Angioedema Follistim AQ follitropin beta Ovulatory Stimulants Forteo teriparatide Parathyroid Hormone for Osteoporosis/Bones Fulyzaq crofelemer HIV/AIDS Fuzeon enfuvirtide HIV/AIDS Ganirelix gonadotropin-releasing hormone Specialized OB/GYN antagonist Gattex glucagon-like peptide 2 analog Gastrointestinal Genotropin somatropin Growth Hormone Gleevec imatinib Oncology Gilenya fingolimod Multiple Sclerosis Gilotrif afatinib Oncology Page 2 of 7
3 Gonal-F follitropin alfa Ovulatory Stimulants Gonal-F RFF follitropin alfa Ovulatory Stimulants Harvoni ledipasvir/sofosbuvir Hepatitis C Hemangeol propranolol Proliferating Infantile Hemangioma Hepsera adefovir dipivoxil Hepatitis B Hetlioz tasimelteon Sedative/Hypnotic Hexalen altretamine Oncology Humatrope somatropin Growth Hormone Humira adalimumab Monoclonal Antibody/Arthritis/Psoriasis/ Crohns/Ankylosing Spondilitis Ibrance palbociclib Oncology Iclusig ponatinib Oncology Imbruvica ibrutinib Oncology Ilaris canakinumab Interleukin Blocker Incivek telaprevir Hepatitis C Increlex mecasermin Growth Hormone Infergen interferon alfacon-1 Interferon Intelence etravirine HIV/AIDS Intron-A interferon alfa-2b Interferon Invirase saquinavir HIV/AIDS Iressa getfitinib Oncology Isentress raltegravir HIV/AIDS Jakafi ruxolitinib Oncology Juxtapid lomitapide Hypercholesterolemia Kaletra lopinavir/ritonavir HIV/AIDS Kalydeco ivacaftor Respiratory Keveyis dichlorphenamide Carbonic Anhydrase Inhibitor Kineret anakinra Immunologic Agents Korlym mifepristone Endocrine/Cushing s disease Kuvan sapropterin dihydrochloride Phenylketonuria Kynamro mipomersen Hypercholesterolemia Lenvima lenvatinib Oncology Letairis ambrisentan Pulmonary Arterial Hypertension leucovorin leucovorin* Folinic Acid for Anemia Lexiva amprenavir HIV/AIDS Lomustine lomustine Oncology Lonsurf trifluridine/tipiracil HCl Oncology Lupron (all products) leuprolide Gonadotropin-releasing hormone analog Luveris lutropin alfa Ovulatory Stimulants Page 3 of 7
4 Lynparza olaparib Oncology Lysodren mitotane Oncology Makena hydroxyprogesterone Hormone Matulane procarbazine Oncology Mekinist trametinib Oncology Menopur menotropins Ovulatory Stimulants Moderiba ribavirin* Antiviral for Hepatitis C Myalept metreleptin Leptin Analog Neumega oprelvekin Interleukin for platelets Neupogen filgrastim Colony Stimulating Factor for use with chemotherapy Nexavar sorafenib Oncology Norditropin somatropin Growth Hormone (all products) Northera droxidopa Neurogenic Orthostatic Hypotension Norvir ritonavir HIV/AIDS Novarel human chorionic gonadotropin Specialized OB/GYN Nutropin (all products) somatropin Page 4 of 7 Growth Hormone Odomzo sonidegib phosphate Oncology Olysio simeprevir Hepatitis C Omnitrope somatropin Growth Hormone Opsumit macitentan Pulmonary Arterial Hypertension Orencia SC abatacept Selective costimulation modulator for RA Orenitram treprostinil Pulmonary Arterial Hypertension Orfadin nitisinone Tyrosinemia Type 1 Otezla apremilast Psoriatic Arthritis Otrexup methotrexate Arthritis/Polyarticular Juvenile Idiopathic Arthritis/Psoriasis Ovidrel choriogonadotropin alfa Specialized OB/GYN Oxsoralen methoxsalen Psoralen Oxsoralen-Ultra methoxsalen Psoralen Panretin gel alitretinoin HIV/AIDS Pegasys peginterferon alfa-2a Hepatitis C Peg-Intron peginterferon alfa-2b Hepatitis C Plegridy peginterferon beta-1a Multiple sclerosis Pomalyst pomalidomide Oncology Praluent alirocumab PCSK-9 inhibitor Pregnyl chorionic gonadotropin Specialized OB/GYN
5 Prezista darunavir HIV/AIDS Procrit epoetin alfa Red blood cell progenitor Profasi chorionic gonadotropin Specialized OB/GYN Promacta eltrombopag olamine Thrombopoietic Agents Pulmozyme dornase alfa Cystic Fibrosis Qutenza Capsaicin Postherpetic Neuralgia Ravicti glycerol phenylbutyrate Nitrogen-binding Agent Rebetol ribavirin* Hepatitis C Rebif interferon beta-1a Multiple Sclerosis Relistor methylnaltrexone bromide Specialty GI drug Repatha evolocumab PCSK-9 inhibitor Rescriptor delavirdine HIV/AIDS Retrovir zidovudine* HIV/AIDS Revatio sildenafil* Pulmonary Arterial Hypertension Revlimid lenalidomide Oncology Reyataz atazanavir HIV/AIDS Ribapak ribavirin* Antiviral for Hepatitis C ribasphere ribavirin* Antiviral for Hepatitis C Ribatab ribavirin* Antiviral for Hepatitis C Rilutek riluzole* Sclerosis Roferon-A interferon alfa-2a recombinant Interferon Sabril vigabatrin Anticonvulsant Saizen somatropin Growth Hormone Sandostatin octreotide Acromegaly, Carcinoid Syndrome, VIPomas Selzentry maraviroc HIV/AIDS Serostim somatropin HIV/AIDS Signifor pasireotide Somatostatin/Cushing s disease Simponi golimumab Anti-tumor necrosis factor drug Sirturo bedaquiline Tuberculosis Somavert pegvisomant Acromegaly Sovaldi sofosbuvir Hepatitis C Sprycel dasatinib Oncology Stelara ustekinumab Interleukin Blocker Stimate nasal desmopressin Vasopressin Analogue spray Stivarga regorafenib Oncology Strensiq asfotase alfa Hypophosphatasia Stribild elvitegravir/cobicistat/emtricitabine/ tenofovir HIV/AIDS Page 5 of 7
6 Sucraid sacrosidase Enzyme replacement Sustiva efavirenz HIV/AIDS Sutent sunitinib Oncology Sylatron peginterferon alfa-2b Oncology Synribo omacetaxine Oncology Tafinlar dabrafenib Oncology Tarceva erlotinib Oncology Targretin bexarotene Oncology Targretin gel bexarotene Oncology Tasigna nilotinib Oncology Tecfidera dimethyl fumarate Multiple Sclerosis Technivie ombitasvir, paritaprevir, ritonavir Hepatitis C Temodar temozolomide Oncology Tev-Tropin somatropin Growth Hormone Thalomid thalidomide Oncology Tivicay dolutegravir HIV/AIDS Tobi tobramycin for inhalation Anti-infective (Cystic Fibrosis) Tobi Podhaler tobramycin for inhalation Anti-infective (Cystic Fibrosis) Tracleer bosentan Pulmonary Arterial Hypertension Triumeq dolutegravir/abacavir/lamivudine HIV/AIDS Trizivir abacavir/lamivudine/zidovudine HIV/AIDS Truvada emtricitabine/tenofovir HIV/AIDS Tybost cobicistat HIV/AIDS Tykerb lapatinib Oncology Tysabri natalizumab Monoclonal Antibody/Multiple Sclerosis Tyvaso treprostinil Pulmonary Arterial Hypertension Tyzeka telbivudine Hepatitis B Valchlor mechlorethamine Oncology Vandetanib vandetanib Oncology Vecamyl mecamylamine Hypertension Ventavis iloprost Pulmonary Arterial Hypertension VePesid etoposide Oncology Versacloz clozapine Antipsychotic agent Victrelis boceprevir Hepatitis C Videx/EC didanosine* HIV/AIDS Viracept nelfinavir HIV/AIDS Viramune nevirapine* HIV/AIDS Viread tenofovir HIV/AIDS Page 6 of 7
7 Votrient pazopanib Oncology Xalkori crizotinib Oncology Xeljanz tofacitinib Immunologic Agent Xeloda capecitabine Oncology Xenazine tetrabenazine Huntington's disease Xtandi enzalutamide Oncology Xyrem gamma hydroxybutyrate Cataplexy Zavesca miglustat Gaucher Disease Zecuity sumatriptan succinate Anti-Migraine Zelboraf vemurafenib Oncology Zerit stavudine* HIV/AIDS Ziagen abacavir* HIV/AIDS Zolinza vorinostat Oncology Zorbtive somatropin Growth Hormone Zydelig Idelaisib Oncology Zytiga abiraterone acetate Oncology Page 7 of 7
Specialty Drug Program RX Benefit Member Guide
Specialty Drug Program RX Benefit Member Guide bcbsm.com Enrollment Form for Walgreens Specialty Pharmacy, LLC. How to place your initial order with Walgreens Specialty Pharmacy: 1) Print and complete
Covered California s 2016 Formularies
Covered California s 2016 Formularies An analysis of the drugs per tier in all 12 health plans that are available for treating and preventing HIV (pp 1 24) and for treating hepatitis B (pp 26 37) and hepatitis
HIV 1. A reference guide for prescription HIV-1 medications
HIV 1 A reference guide for prescription HIV-1 medications Several different kinds of antiretroviral drugs are currently used to treat HIV-1 infection. These medicines are the ones most commonly used in
HIV MEDICATIONS AT A GLANCE. Atripla 600/200/300 mg tablet 02300699 1 tablet daily. Complera 200/25/300 mg tablet 02374129 1 tablet daily
HIV MEDICATIONS AT A GLANCE Generic Name Trade Name Strength DIN Usual Dosage Single Tablet Regimen (STR) Products Efavirenz/ emtricitabine/ Emtricitabine/ rilpivirine/ elvitegravir/ cobicistat/ emtricitabine/
Drugs Requiring Prior Authorization. Olysio. Subsys. Prolia. Tecfidera
Abstral Acthar Hp Adcirca Adempas Affinitor Amitiza Amitriptyline Ampyra Androgel Androderm Androxy Aranesp Arcalyst Aubagio Avonex Bosulif Bydureon Byetta Cimzia Cinryze Clomipramine Cometriq Copaxone
REVISING SPECIALTY TIERS
WHITE PAPER REVISING SPECIALTY TIERS PROTECTING MEDICARE PART D BENEFICIARIES FROM BURDENSOME COST SHIFTING Gary G., Michigan Gary thought he had his financial assistance grant set up to cover his out-of-pocket
MEDICAL ASSISTANCE BULLETIN
ISSUE DATE August 20, 2015 SUBJECT EFFECTIVE DATE September 28, 2015 MEDICAL ASSISTANCE BULLETIN NUMBER 99-15-08 BY Specialty Pharmacy Drug Program Pharmacy Services Leesa M. Allen, Deputy Secretary Office
Humana 2015 Autorización previa
Humana 2015 Autorización previa Los medicamentos a continuación requerirán autorización previa en 2015. Para información sobre el nivel de copago, visite Humana.com. Abstral 100 mcg sublingual tablet Abstral
PATIENT ASSISTANCE PROGRAMS
PATIENT ASSISTANCE PROGRAMS Definitions SAP Class I Class II BC Cancer Agency Health Canada Special Access Program Reimbursed for active cancer or approved treatment or approved indication only Reimbursed
North Carolina Marketplace Plans with More Affordable Drug Cost Sharing for People with HIV
North Carolina Marketplace Plans with More Affordable Drug Cost Sharing for People with HIV Of North Carolina s marketplace insurance offerings, only Blue Cross Blue Shield s plans are potentially affordable
Medical School for Actuaries. June 12, 2013. Baltimore, Maryland
Medical School for Actuaries June 12, 2013 Baltimore, Maryland Developments in the Treatment of Conditions Treated with Specialty Mediations (Cancer, MS, RA, Hemophilia) Mark S. Matusik, PharmD Developments
Prescription Drug Benefit Description
Prescription Drug Benefit Description Herein called Description Prescription Drug Program For State of Kansas Employees Health Plan This booklet describes the Prescription Drug benefits available through
CO-PAY PROGRAMS FOR HIV and Hepatitis
CO-PAY PROGRAMS FOR HIV and Hepatitis CO-PAY PROGRAMS FOR HIV These programs offer assistance to people with private health insurance for the co-payments they have to make at the pharmacy for their HIV
Marketplace Health Plans Template Assessment Tool October 2014
Marketplace Health Plans Template Assessment Tool October 2014 Beginning in January 2015, state and federal Marketplaces (aka exchanges) will again offer a range of insurance plans called qualified health
Local Coverage Article: Self-Administered Drug Exclusion List (A51866)
Local Coverage Article: Self-Administered Drug Exclusion List (A51866) Contractor Information Contractor Name Novitas Solutions, Inc. Article Information General Information Article ID A51866 General Article
Specialty Pipeline Update
CLINICAL SOLUTIONS Drug Insights > June 2014 Specialty Pipeline Update New Drug Information Eloctate (recombinant factor VIII Fc fusion protein): Biogen received FDA approval for their hemophilia A for
Great-West s Drug Prior Authorization
Great-West s Drug Prior Authorization Great-West Life s prior authorization process is designed to provide an effective approach to managing claims for specific prescription drugs. Approval for coverage
862060_Rec Drug Guide.qxd 2/5/14 1:06 PM Page 1. Recreational Drugs and HIV Antiretrovirals. A Guide to Interactions for Clinicians
862060_Rec Drug Guide.qxd 2/5/14 1:06 PM Page 1 Recreational Drugs and HIV Antiretrovirals A Guide to Interactions for Clinicians 2014 862060_Rec Drug Guide.qxd 2/5/14 1:06 PM Page 2 Recreational Drugs
Specialty drug trend
2 0 0 8 Specialty drug trend r e p o r t Specialty Pharmacy A n E x p r e s s S c r i p t s C o m p a n y Lead Authors Emily Cox, PhD, RPh Yakov Svirnovskiy, MA Chris Peterson, PharmD Aimee Tharaldson,
encourages correct prescription drug use for a particular diagnosis, promotes the safe use of prescription drugs, and helps reduce drug costs.
Prior Authorization Your health plan participates in a Prior Authorization (PA) program for specific prescription drugs. This means that Caremark must review certain information provided by your doctor
It s In The Cards: Pharmaceutical Co-pay and Patient Assistance Programs. Jeff Berry Editor, Positively Aware
It s In The Cards: Pharmaceutical Co-pay and Patient Assistance Programs Jeff Berry Editor, Positively Aware PAPs, Co-Pays, and ADAPs, Oh My! Patient Assistance Programs (PAPs) provide free or low-cost
Helpful HIV Medication Tables for Pharmacists
861837_Pharmguide.qxd 2/5/14 12:55 PM Page 1 Helpful HIV Medication Tables for Pharmacists New York/New Jersey AIDS Education & Training Center (AETC) www.nynjaetc.org Winter 2014 861837_Pharmguide.qxd
Drug Treatment Program Update
Drug Treatment Program Update As of May 211 Drug Treatment Program Update A key component of the Centre s mandate is to monitor the impact of HIV/AIDS on British Columbia. The Centre provides essential
Special Authorization
Special Authorization Certain medications in the Reformulary require Special Authorization from your insurance company before your prescription is eligible for coverage. What is Special Authorization?
Systematic literature search: PICO questions
BHIVA Treatment Guidelines 2014: Systematic literature search questions Page 1 of 5 Systematic literature search: PICO questions 2.1 Questions and PICO criteria Databases: Medline, Embase, Cochrane Library,
Provider Manual. This manual is to help you learn more about The Ohio State University s medical plans, administered by OSU Health Plan Inc.
2014 Provider Manual This manual is to help you learn more about The Ohio State University s medical plans, administered by OSU Health Plan Inc. We hope you find this information and the enclosed documents
STAT Bulletin. Drug Therapy Guideline Updates. May 11, 2012 Volume: 18 Issue: 12
STAT Bulletin May 11, 2012 Volume: 18 Issue: 12 To: All primary care physicians and specialists Contracts Affected: All Lines of Business Drug Therapy Guideline Updates Why you re receiving this Stat What
Alameda Alliance for Health SPECIALTY PHARMACY PROGRAM FOR ALLIANCE MEDI-CAL AND GROUP CARE MEMBERS PROGRAM DESCRIPTION
Alameda Alliance for Health SPECIALTY PHARMACY PROGRAM FOR ALLIANCE MEDI-CAL AND GROUP CARE MEMBERS PROGRAM DESCRIPTION Contents Page Program Overview 1 Process for Obtaining Authorization 2 Contacts 2
ClearScript Prior Authorization Drug List
ClearScript Prior Authorization Drug List Prior authorization is a cost-savings program intended to ensure that medications are utilized in a manner that is consistent with your pharmacy benefit. For the
ACA Insurance Enrollment for People living with HIV in North Carolina
ACA Insurance Enrollment for People living with HIV in North Carolina A Guide for the HIV Community In 2015, people living with HIV should take a fresh look at the insurance marketplace. Coverage will
Drug Formulary Update, July 2014 Commercial and State Programs
Drug ormulary Update, July 2014 Commercial and State Programs Updates to the HealthPartners Drug ormularies are listed below. Changes start July 1 unless noted otherwise. Updates apply to all Commercial
Drug List Limitations, Exclusions and Preauthorization Criteria
Blue Cross and Blue Shield of New Mexico (BCBSNM) provides coverage of many drugs for our members. Effective communication about specific drug limitations is important for consistent benefit administration
The Antiretroviral. Pregnancy Registry. Interim Report VOL. 28, NO. 1 1 JANUARY 1989 THROUGH 31 JANUARY 2016. Interim Report. (Issued: June 2016)
The Antiretroviral The Antiretroviral Pregnancy Registry Pregnancy Registry Interim Report VOL. 28, NO. 1 1 JANUARY 1989 THROUGH 31 JANUARY 2016 Interim Report (Issued: June 2016) VOL. (Expiration: 28,
Immune Modulating Drugs Prior Authorization Request Form
Patient: HPHC member ID #: Requesting provider: Phone: Servicing provider: Diagnosis: Contact for questions (name and phone #): Projected start and end date for requested Requesting provider NPI: Fax:
Medicare Part D Drugs that Require Prior-Authorization Effective 12/01/2015
Medicare Drugs that Require Prior- Effective 12/01/2015 Prior Actemra IV Actemra All FDAapproved Required Medical Information Age Prescriber 2. For Rheumatoid Arthritis: Patient must have tried and failed
Medicare Part D Plans Deliver Significant Savings on Innovative, Breakthrough Medicines
Medicare Part D Plans Deliver Significant Savings on Innovative, Breakthrough Medicines Survey Finds Private Sector Negotiations Provide Both Savings and Choice, Making Government Interference Unnecessary
Comprehensive Case Management Reassessment
Comprehensive Case Management Reassessment Reassessment Date: Date of previous Assessment/Reassessment: Name: Client ID # Address: If Reassessment early or late explain: Current HIV Status: Asymptomatic
GENERAL INSTRUCTIONS FOR COMPLETING THE HIV TEST FORM
GENERA INSTRUCTIONS FOR COMPETING THE This form is designed to be read by an Optical Character Recognition (OCR) scanner. The legibility of this form depends on the quality of the a hand written and selected
Antiretroviral Patient Medication Information Sheets Table of Contents
Antiretroviral Patient Medication Information Sheets Table of Contents 1. About this Resource, Disclaimer, Instructions for Use 2. General information sheet - Provide this to all patients 3. Drug Specific
Effective Date: 6/3/14
North Shore-Long Island Jewish Health System, Inc. Long Island Jewish Medical Center PATIENT CARE SERVICES POLICY TITLE: ORDERING, ADMINISTRATION AND DISPOSAL OF ORAL CHEMOTHERAPEUTIC AGENTS Prepared by:
ACNE PRODUCTS. Affected Drugs: Epiduo Retin-A Tretinoin. Covered Uses: All FDA-approved indications not otherwise excluded from Part D
ACNE PRODUCTS Epiduo Retin-A Tretinoin Exclusion Criteria: Esthetic purposes N/A N/A TSA 2015 Royal, Classic, Vital and Vital Plus Formulary Page 1 of 148 ACTEMRA Actemra Exclusion Criteria: 1) Active
STATE HEALTH REFORM IMPACT MODELING PROJECT. Georgia
STATE HEALTH REFORM IMPACT MODELING PROJECT Georgia January 2013 Prepared by the Center for Health Law and Policy Innovation of Harvard Law School and the Treatment Access Expansion Project BACKGROUND
Specialty Pharmacy: Understanding the Market and Solution. Your Goals. Presented by Chris Brown November 2009
Specialty Pharmacy: Understanding the Market and Solution Presented by Chris Brown November 2009 Your Goals What What is a Specialty is a specialty Medication? medication? Specialty drugs are injectable,
Pain management for cancer patients Acute Ischemic Stroke. Hemophilia, Von willebrand disease & Bleeding disorders. Infectious Disease
Cigna Specialty Pharmacy Services Limited Distribution and Risk Evaluation Mitigation (RE) Drug List Last updated on 04/06/2015 Medication Brand Name Condition Actemra Rheumatroid Arthritis Acthar Seizure
Opioid Pain and Addiction Management Medications Drug. Interactions with HIV Antiretrovirals. A Drug Interaction Guide for Clinicians.
857106_Pain Bro.qxd 6/11/13 7:49 AM Page 1 Opioid Pain and Addiction Management Medications Drug Interactions with HIV Antiretrovirals A Drug Interaction Guide for Clinicians Spring 2013 NY/NJ AIDS Education
HIV/AIDS 2014 REPORT MEDICINES IN DEVELOPMENT. Contents. Medicines and Vaccines in Development for HIV Infection
MEDICINES IN DEVELOPMENT HIV/AIDS PRESENTED BY AMERICA S BIOPHARMACEUTICAL RESEARCH COMPANIES 2014 REPORT Biopharmaceutical Company Researchers Are Developing More Than 40 Medicines and Vaccines For HIV
Chemotherapy regimen: Dose adjusted EPOCH
Chemotherapy regimen: Dose adjusted EPOCH Agents involved Etoposide 50 mg/m 2 /d continuous IV infusion D 1 4 Doxorubicin 10 mg/m 2 /d continuous IV infusion D 1 4 Vincristine 0.4 mg/m 2 /d IV continuous
The Newcastle upon Tyne Hospitals NHS Foundation Trust. Handling, Segregation and Disposal of Cytostatic and Cytotoxic Waste
The Newcastle upon Tyne Hospitals NHS Foundation Trust Handling, Segregation and Disposal of Cytostatic and Cytotoxic Waste Version.: 1.1 Effective From: 20 January 2016 Expiry Date: 20 January 2019 Date
Self-injectable, infused and oral specialty drugs 2014 Aetna Specialty CareRx SM Benefits Plan Drug List
Quality health plans & benefits Healthier living Financial well-being Intelligent solutions Self-injectable, infused and oral specialty drugs 2014 Aetna Specialty CareRx SM Benefits Plan Drug List 05.03.382.1
ACTEMRA. Cigna Medicare Rx (PDP) 2014 Cigna Medicare Rx Secure Plan (PDP) Formulary. Products Affected Actemra. Prior Authorization Criteria
Cigna Medicare Rx (PDP) Medicare Part D Prescription Drug Plans 2014 Cigna Medicare Rx Secure Plan (PDP) Formulary Prior Authorization ACTEMRA Products Affected Actemra PA Details Age Other Authorization
South CarolinaJanuary 2013
STATE HEALTH REFORM IMPACT MODELING PROJECT South CarolinaJanuary 2013 Prepared by the Center for Health Law and Policy Innovation of Harvard Law School and the Treatment Access Expansion Project BACKGROUND
January 1, 2016 At A Glance. CSEA Civil Service Employees Association
January 1, 2016 At A Glance CSEA Civil Service Employees Association For Employees of the State of New York represented by Civil Service Employees Association (CSEA) and for their enrolled Dependents;
UMASTER PREFERRED DRUG LIST (DRUG FORMULARY) Effective July 1, 2015 RA05/15.654
UMASTER PREFERRED DRUG LIST (DRUG FORMULARY) Effective July 1, 2015 1PU 2PU 3PU 4PU UPU UPU UPU UPU P P P P P Tier Master List (PDL) (Drug Formulary) Effective July 1, 2015 THE BLUEGRASS FAMILY HEALTH
STATE HEALTH REFORM IMPACT MODELING PROJECT. Alabama
STATE HEALTH REFORM IMPACT MODELING PROJECT Alabama January 2013 Prepared by the Center for Health Law and Policy Innovation of Harvard Law School and the Treatment Access Expansion Project BACKGROUND
Review of the List of High-Cost Medicines used by the Dominican Republic s Protected Diseases Program and Planning of Purchases for 2015
Review of the List of High-Cost Medicines used by the Dominican Republic s Protected Diseases Program and Planning of Purchases for 2015 July 2014 Review of the List of High-Cost Medicines Used by the
Pharmacy Policy Bulletin
Pharmacy Policy Bulletin Title: Policy #: Pulmonary Arterial Hypertensive (PAH) agents Rx.01.83 Application of pharmacy policy is determined by benefits and contracts. Benefits may vary based on product
2013 Prior Authorization (PA) Criteria
2013 Prior Authorization (PA) Criteria Certain drugs require prior authorization from EmblemHealth Medicare PDP Medicare Plans. This means that your doctor must contact us to get approval before prescribing
ACS CAN Examination of Cancer Drug Coverage and Transparency in the Health Insurance Marketplaces
ACS CAN Examination of Cancer Drug Coverage and Transparency in the Health Insurance Marketplaces Executive Summary November 18, 2015 In 2014, the American Cancer Society Cancer Action Network (ACS CAN)
State Health Reform Impact Modeling Project Florida
State Health Reform Impact Modeling Project Florida January 2013 Prepared by the Center for Health Law and Policy Innovation of Harvard Law School and the Treatment Access Expansion Project Questions may
Prescription Drug Benefit
Prescription Drug Benefit The Cleveland Clinic Employee Health Plan (EHP) Total Care Prescription Drug Benefit is administered through CVS Caremark. CVS Caremark has a dedicated, toll-free Customer Service
B.C. HIV/AIDS Drug Treatment Program
B.C. HIV/AIDS Drug Treatment Program Monthly Report January 215 215 BC Centre for Excellence in HIV/AIDS DISCLAIMER: This document is published by the British Columbia Centre for Excellence in HIV/AIDS
SPECIAL AUTHORIZATION GUIDELINES
91B ALBERTA DRUG BENEFIT LIST SPECIAL AUTHORIZATION GUIDELINES 37BSpecial Authorization Policy 90BDrug Products Eligible for Consideration by Special Authorization Drug Products may be considered for coverage
Maryland. State Health Reform Impact Modeling Project
State Health Reform Impact Modeling Project Maryland January 2013 Prepared by the Center for Health Law and Policy Innovation of Harvard Law School and the Treatment Access Expansion Project Background
New Jersey. State Health Reform Impact Modeling Project
State Health Reform Impact Modeling Project New Jersey January 2013 Prepared by the Center for Health Law and Policy Innovation of Harvard Law School and the Treatment Access Expansion Project Background
N/A N/A N/A. Supporting statement of diagnosis from the N/A. physician and documented trial of 1 generic. formulary alternative
Actimmune Amlodipine Androderm Anticonvulsant Antidepressants Antineoplastics Antipsychotics Arcalyst Butalbital Colony Stimulating Factors ESRD Therapy Actimmune Norvasc Androderm Banzel Keppra Mysoline
State Health Reform Impact Modeling Project Tennessee
State Health Reform Impact Modeling Project Tennessee January 2013 Prepared by the Center for Health Law and Policy Innovation of Harvard Law School and the Treatment Access Expansion Project Background
This information is also available in large print. Call 1-800-286-4242. TTY users should call toll-free 1-800-361-2629.
Your prescription drug program 2015 This information is also available in large print. Call 1-800-286-4242. TTY users should call toll-free 1-800-361-2629. Table of Contents Your Prescription Drug Program...
Winter 2013. Changing landscapes, pipeline products and plan sponsor impact
Winter 2013 Changing landscapes, pipeline products and plan sponsor impact Changing landscapes, pipeline products and plan sponsor impact The pharmaceutical landscape is changing as is the profile of blockbuster
Harvoni (Ledipasvir/Sofosbuvir) Treatment Agreement
Harvoni (Ledipasvir/Sofosbuvir) Treatment Agreement Liver Disease & Hepatitis Program Providers: Brian McMahon, MD; Youssef Barbour, MD; Lisa Townshend-Bulson, FNP-C; Annette Hewitt, FNP-C; Prabhu Gounder,
Specialty Pharmacy. Business Plan. July 8, 2013. 2013 RUSH University Medical Center
Specialty Pharmacy Business Plan July 8, 2013 Specialty Pharmaceuticals What are they? Biotech/gene-based therapy Require special handling Newer products oral or self- administered One third have REMS
Heritage UNDERWRITING GUIDE & RATE BOOK. Equitable Equitable Life & Casualty Insurance Company. A Whole Life Plan To Protect Those You Love
UNDERWRITING GUIDE & RATE BOOK Heritage P R O T E C T O R A Whole Life Plan To Protect Those You Love UW Guide (9/13) Equitable Equitable Life & Casualty Insurance Company Table of Contents General Information......................................................
Drug Formulary Update, July 2013
Drug Formulary Update, July 2013 Updates to the HealthPartners Drug Formularies are listed below. Updates for the Commercial Drug Formularies and the Minnesota Health Care Programs (Medicaid and Minnesota
COVERAGE MANAGEMENT PROGRAMS
COVERAGE MANAGEMENT PROGRAMS The purpose of coverage management programs is to help improve the quality of care by encouraging the right patient and provider behaviors to avoid compromised care and unnecessary
District of Columbia
STATE HEALTH REFORM IMPACT MODELING PROJECT District of Columbia January 2013 Prepared by the Center for Health Law and Policy Innovation of Harvard Law School and the Treatment Access Expansion Project
comparison of access and reimbursement environments A report benchmarking Australia s access to new medicines Edition 1
comparison of access and reimbursement environments A report benchmarking Australia s access to new medicines Edition 1 March 2015 Welcome to the first COMPARE report. This report provides information
DRUG TREND REPORT UPDATED MAY 2013 BY THE RESEARCH AND NEW SOLUTIONS LAB. DrugTrendReport.com
DRUG REPORT UPDATED MAY 2013 BY THE RESEARCH AND NEW SOLUTIONS LAB DrugTrendReport.com The Express Scripts Drug Trend Report provides the healthcare industry s most detailed analysis of prescription drug
PULMONARY ARTERIAL HYPERTENSION AGENTS
Approvable Criteria: PULMONARY ARTERIAL HYPERTENSION AGENTS Brand Name Generic Name Length of Authorization Revatio Sildenafil citrate Calendar Year Adcirca Tadalafil Calendar Year Letairis Ambrisentan
Drugs That Require Prior Authorization (PA) Before Being Approved for Coverage PRIOR AUTHORIZATION MEDICATIONS
That Require Prior Authorization (PA) Before Being Approved for Coverage PRIOR AUTHORIZATION MEDICATIONS ACNE Approve for those 12 years of age and older AVITA, RETIN-A MICRO, TRETINOIN ACTHAR HP All FDA-approved
CONNECTICARE, INC. & AFFILIATES
CONNECTICARE, INC. & AFFILIATES INSERT PAGE FOR PRE-CERTIFICATION AND PRE- AUTHORIZATION LISTS UPDATE Applies to all ConnectiCare health plans, except the ConnectiCare Network USA-PPO Plan and as otherwise
STATE HEALTH REFORM IMPACT MODELING PROJECT. North Carolina
STATE HEALTH REFORM IMPACT MODELING PROJECT North Carolina December 2012 Prepared by the Center for Health Law and Policy Innovation of Harvard Law School and the Treatment Access Expansion Project Questions
1. Phosphodiesterase Type 5 Enzyme Inhibitors: Sildenafil (Revatio), Tadalafil (Adcirca)
This policy has been developed through review of medical literature, consideration of medical necessity, generally accepted medical practice standards, and approved by the IEHP Pharmacy and Therapeutic
ACTEMRA. Products Affected. Actemra
ACTEMRA Actemra Covered Uses Age Other All FDA-approved indications not otherwise excluded from Part D. Plus patients already started on tocilizumab for a Covered Use. Tocilizumab should not be given in
HIV ONCOLOGY HANDBOOK. Antiretroviral Interactions with Chemotherapy Regimens. Alison Wong, B.pharm., M.Sc. Alice Tseng, Pharm.D.
2014 HIV ONCOLOGY HANDBOOK Antiretroviral Interactions with Chemotherapy Regimens Alison Wong, B.pharm., M.Sc. Chronic Viral Illness Service McGill University Health Centre Montreal, QC Alice Tseng, Pharm.D.,
HealthPartners, Inc. 2013 Medicare Part D Formulary ID 13142, Version 22 Prior Authorization Criteria. Last Updated: 11/01/2013
ACTEMRA Actemra (1) DIAGNOSIS OF MODERATELY TO SEVERELY ACTIVE RHEUMATOID ARTHRITIS, OR (2) JUVENILE IDIOPATHIC ARTHRITIS, AND (3) DOCUMENTATION OF MEDICAL CONTRAINDICATIONS OR FAILURE WITH ENBREL OR HUMIRA.
All FDA-approved indications not otherwise excluded from Part D. Plus patients already started on tocilizumab for a Covered Use.
Prior Authorization CY 14 MNP Open 4 Tier - UMWD - Oct14 Last Updated: 04/01/2015 ACTEMRA Actemra intravenous solution 200 mg/10 ml (20 mg/ml) PA Covered Uses Age Other Details All FDA-approved indications
DEPARTMENT OF DEFENSE PHARMACY AND THERAPEUTICS COMMITTEE RECOMMENDATIONS INFORMATION FOR THE UNIFORM FORMULARY BENEFICIARY ADVISORY PANEL
DEPARTMENT OF DEFENSE PHARMACY AND THERAPEUTICS COMMITTEE RECOMMENDATIONS INFORMATION FOR THE UNIFORM FORMULARY BENEFICIARY ADVISORY PANEL I. UNIFORM FORMULARY REVIEW PROCESS Under 10 United States Code
All FDA-approved indications not otherwise excluded from Part D. Plus patients already started on tocilizumab for a Covered Use.
Prior Authorization Paramount Medicare Formulary 2014 Formulary ID: 14170. Version 22. CMS approved 10/28/2014. Last Updated: 10/31/2014 ACTEMRA Products Affected Actemra INJ 162MG/0.9ML, 200MG/10ML PA
Study Support Materials Cover Sheet
Study Support Materials Cover Sheet Document Title ESCALATE Patient Brochure Intended Audience This brochure is designed to be given to potentially eligible patients as a take-home summary of key information
Access and coverage of antiretroviral drugs through Canada s provincial and territorial drug programs
Access and coverage of antiretroviral drugs through Canada s provincial and territorial drug programs Provinces/Territory Drug Dose Form Alberta British Columbia Manitoba New Brunswick Newfoundland & Labrador
Bristol-Myers Squibb and Gilead Sciences, LLC 50
Patient Information ATRIPLA (uh TRIP luh) Tablets ALERT: Find out about medicines that should NOT be taken with ATRIPLA. Please also read the section "MEDICINES YOU SHOULD NOT TAKE WITH ATRIPLA." Generic
2015 PA CRITERIA. UCare for Seniors is an HMO-POS plan with a Medicare contract. Enrollment in UCare for Seniors depends on contract renewal.
2015 PA CRITERIA UCare for Seniors requires your physician to get prior authorization for certain drugs. This means that you will need to get approval from UCare for Seniors before you fill your prescriptions.
Prior Authorization Criteria 2014
Prior Authorization Criteria 2014 For information on obtaining an updated coverage determination or an exception to a coverage determination please contact Easy Choice Health Plan of New York s Member
Drugs That Require Prior Authorization (PA) Before Being Approved for Coverage PRIOR AUTHORIZATION MEDICATIONS
Drugs That Require Prior Authorization (PA) Before Being Approved for Coverage You will need authorization by your Senior Blue HMO or Forever Blue Medicare PPO plan before filling prescriptions for the
Rheumatic Diseases, Psoriasis, and Crohn s Disease
Rheumatic Diseases, Psoriasis, and Crohn s Disease What does this handout cover? This handout has information about rheumatic disease, psoriasis, and Crohn s disease. It also has information on how these
April 30, 2009. The Honorable Edward M. Kennedy Chairman Committee on Health, Education, Labor, and Pensions United States Senate
United States Government Accountability Office Washington, DC 20548 April 30, 2009 The Honorable Edward M. Kennedy Chairman Committee on Health, Education, Labor, and Pensions United States Senate Subject:
Development of the market of special care drugs
Forecast Special Care Drugs Development of the market of special care drugs IGES Institut Berlin, April 6th 21 I G E S I n s t i t ut G m bh w w w. i ges.de Friedrichstraße 18 1117 Berlin Germany +49 3
Antiretroviral Treatment Options for Patients on Directly Acting Antivirals for Hepatitis C. Daclatasvir (Daklinza, DCV, BMS-790052)
Antiretroviral Treatment Options for Patients on Directly Acting Antivirals for Hepatitis C PIs: atazanavir PIs: other Simeprevir with ritonavir- or cobicistat boosted PIs (significant simeprevir AUC).
Prior Authorization FID 16157 VER.7 UPDATED 8/2015
Prior Authorization FID 16157 VER.7 UPDATED 8/2015 Prior Authorization 2016 MAPD Leon 3 Tier Last Updated: 10/22/2015 ACTEMRA Products Affected Actemra INJ 162MG/0.9ML PA Details Other 1 ACTIMMUNE Products
Hepatitis C Virus and HIV Co-infection 2015 Update. Mia N. Barnes, Pharm.D., BCPS HIV CPE Training Program for Pharmacists February 8, 2015
Hepatitis C Virus and HIV Co-infection 2015 Update Mia N. Barnes, Pharm.D., BCPS HIV CPE Training Program for Pharmacists February 8, 2015 1 Statement of Disclosure Presenter has no relevant financial
Michał Pilkiewicz Country Manager IMS Health Poland
The Pharmaceutical Market in Poland - government regulation, pricing and reimbursement of medicines, in particular What is the influence on the market situation? Michał Pilkiewicz Country Manager IMS Health